Phosphatidylserine-Targeting Immuno-Biologicals for Cancer and Viral Treatment
Rutgers Inventor(s): Sergei V. Kotenko; Raymond B. Birge; Viralkumar Davra
Awarded: April 2019
Summary: Cancers and viruses suppress host immune responses by “masking themselves” with phosphatidylserine (PS), a phospholipid that becomes exposed on the surface of apoptotic or stressed cells abundantly present in tumor microenvironment and in sites of virus infection. Rutgers scientists have developed multifunctional PS-targeting proteins that block PS-mediated immunosuppression and at the same time stimulate host immunity through the localized-delivery and combined action of type I and type III interferons (IFNs). These first-in-class proteins have demonstrated strong antiviral and anti-tumor potencies in mouse disease models.
Market Applications:
- Cancer Therapeutics
- Antiviral Therapeutics
- Disease Prevention/Treatment
